Urine Metabolomics Linked to Clinical Parameters of Asthma

This article originally appeared here.
Share this content:
Urine Metabolomics Linked to Clinical Parameters of Asthma
Urine Metabolomics Linked to Clinical Parameters of Asthma

MONDAY, May 23, 2016 (HealthDay News) -- Increased urine metabolomic lipid metabolites are associated with clinical parameters in non-obese asthma patients, according to a study published online May 18 in Allergy.

Claudia Chaves Loureiro, M.D., Ph.D., from the Centro Hospitalar e Universitário de Coimbra in Portugal, and colleagues conducted an observational and exploratory study to examine the correlation between oxidative stress extension, eosinophilic inflammation, and disease severity in asthma patients. Metabolomics was performed using solid phase microextraction followed by comprehensive two-dimensional gas chromatography coupled to mass spectrometry with a high resolution time of flight analyzer.

The researchers established a reduced data set comprising 34 aliphatic alkanes and aldehydes. Obese subjects were excluded from the analysis. Significant models were seen for clinical parameters, including severity of asthma score, forced expiratory volume in one second, and Th2 inflammatory biomarkers (FeNO, blood eosinophils, and seric immunoglobulin E).

"Non-obese asthmatics had increased urine metabolomic lipid metabolites associated with clinical parameters such as lung function, eosinophilic inflammation, and severity," the authors write. "Nevertheless, considering our sample size, the obtained results require further validation using a much larger sample cohort."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »